Xortx Therapeutics (TSE:XRTX) has released an update.
XORTX Therapeutics has announced the addition of biotech veteran Abigail Jenkins to its Board of Directors, who brings over two decades of experience in commercializing renal and cardiovascular therapies. Jenkins’ extensive background in guiding drugs from research to market is expected to greatly benefit XORTX as they transition towards the commercialization phase for their advanced clinical products. The company, specializing in treatments for progressive kidney disease, has granted Jenkins stock options as part of her appointment.
For further insights into TSE:XRTX stock, check out TipRanks’ Stock Analysis page.
